BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 6407876)

  • 1. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.
    Alvarez F; Faundes A; Johansson E; Coutinho E
    Fertil Steril; 1983 Jul; 40(1):120-3. PubMed ID: 6407876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovulation inhibition following vaginal administration of pills containing norethindrone and mestranol.
    Coutinho EM; Silva AR; Carreira C; Barbosa I
    Contraception; 1984 Feb; 29(2):197-202. PubMed ID: 6723313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
    Landgren BM; Diczfalusy E
    Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
    Landgren BM; Johannisson E; Masironi B; Diczfalusy E
    Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
    Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
    Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of vaginal administration of low-dose oral contraceptive tablets on human ovulation.
    Souka AR; el Sokkary H; Kamel M; Hassan M
    Contraception; 1986 Apr; 33(4):365-71. PubMed ID: 3731776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
    Mishell DR; Moore DE; Roy S; Brenner PF; Page MA
    Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
    Cekan SZ; Jia M; Landgren BM; Diczfalusy E
    Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
    Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
    Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vaginal contraceptive pill.
    Coutinho E
    IPPF Med Bull; 1985 Feb; 19(1):2-3. PubMed ID: 12339969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
    Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
    Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
    Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
    Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
    Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration.
    Stanczyk FZ; Hiroi M; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
    Contraception; 1975 Sep; 12(3):279-98. PubMed ID: 1164847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovulation suppression in women following vaginal administration of oral contraceptive tablets.
    Coutinho EM; Coutinho EJ; Gonçalves MT; Barbosa IC
    Fertil Steril; 1982 Sep; 38(3):380-1. PubMed ID: 6811333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels.
    Ory SJ; Hammond CB; Yancy SG; Hendren RW; Pitt CG
    Am J Obstet Gynecol; 1983 Mar; 145(5):600-5. PubMed ID: 6402933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.